Invention Grant
US07645338B2 Crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide
失效
(E)-2-(5-氯噻吩-2-基)-N - {(3S)-1 - [(1S)-1-甲基-2-吗啉-4-基-2-氧代乙基] - -2-氧代吡咯烷-3-基}乙烯磺酰胺
- Patent Title: Crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide
- Patent Title (中): (E)-2-(5-氯噻吩-2-基)-N - {(3S)-1 - [(1S)-1-甲基-2-吗啉-4-基-2-氧代乙基] - -2-氧代吡咯烷-3-基}乙烯磺酰胺
-
Application No.: US10537645Application Date: 2003-12-04
-
Publication No.: US07645338B2Publication Date: 2010-01-12
- Inventor: Philip C. Dell 'Orco , Henry Anderson Kelly , Gita Punjabhai Shah , Nigel Stephen Watson , Robert John Young
- Applicant: Philip C. Dell 'Orco , Henry Anderson Kelly , Gita Punjabhai Shah , Nigel Stephen Watson , Robert John Young
- Applicant Address: GB Greenford
- Assignee: Glaxo Group Limited
- Current Assignee: Glaxo Group Limited
- Current Assignee Address: GB Greenford
- Agent Bonnie L. Deppenbrock
- Priority: GB0228533.6 20021206
- International Application: PCT/EP03/13800 WO 20031204
- International Announcement: WO2004/052878 WO 20040624
- Main IPC: C30B29/54
- IPC: C30B29/54
![Crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide](/abs-image/US/2010/01/12/US07645338B2/abs.jpg.150x150.jpg)
Abstract:
The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
Public/Granted literature
- US20060124049A1 Crystalline form Public/Granted day:2006-06-15
Information query
IPC分类: